Premium
Consensus guidelines on the use of bisphosphonate therapy in children and adolescents
Author(s) -
Simm Peter J,
Biggin Andrew,
Zacharin Margaret R,
Rodda Christine P,
Tham Elaine,
Siafarikas Aris,
Jefferies Craig,
Hofman Paul L,
Jensen Diane E,
Woodhead Helen,
Brown Justin,
Wheeler Benjamin J,
Brookes Denise,
Lafferty Antony,
Munns Craig F
Publication year - 2018
Publication title -
journal of paediatrics and child health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.631
H-Index - 76
eISSN - 1440-1754
pISSN - 1034-4810
DOI - 10.1111/jpc.13768
Subject(s) - medicine , osteogenesis imperfecta , guideline , osteoporosis , avascular necrosis , pediatrics , cerebral palsy , intensive care medicine , evidence based medicine , physical therapy , surgery , alternative medicine , pathology , femoral head
Bisphosphonate therapy is the mainstay of pharmacological intervention in young people with skeletal fragility. The evidence of its use in a variety of conditions remains limited despite over three decades of clinical experience. On behalf of the Australasian Paediatric Endocrine Group, this evidence‐based consensus guideline presents recommendations and discusses the graded evidence (using the GRADE system) for these recommendations. Primary bone fragility disorders such as osteogenesis imperfecta are considered separately from osteoporosis secondary to other clinical conditions (such as cerebral palsy, Duchenne muscular dystrophy). The use of bisphosphonates in non‐fragility conditions, such as fibrous dysplasia, avascular necrosis, bone cysts and hypercalcaemia, is also discussed. While these guidelines provide an evidence‐based approach where possible, further research is required in all clinical applications in order to strengthen the recommendations made.